BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. MATERIALS AND METHODS: We analyzed 26 pretreatment clinical variables in 850 NSCLC patients treated in the randomized Eastern Cooperative Oncology Group 4599 study. Univariate and multivariate analyses were performed to identify prognostic factors. Cox regression with 50% randomly sampled data was used to build nomograms with a prognostic score assigned to each factor. The model was validated with the remaining 50% of data. RESULTS: Eleven poor factors for OS (hazard ratio) were as follows: skin metastasis (4.49), body mass index less than 18.5 (2.09), increased serum lactate dehydrogenase (1.74), adrenal metastasis (1.52), performance status greater than 0 (1.45), low serum albumin (1.45), men (1.39), bone metastasis (1.39), large cell/not otherwise specified histology (1.29), mediastinal nodal metastasis (1.23), and treatment without bevacizumab (1.18). Seven poor factors for PFS were as follows: skin metastasis (3.13), treatment without bevacizumab (1.52), bone metastasis (1.41), liver metastasis (1.40), low serum albumin (1.39), performance status greater than 0 (1.21), and mediastinal nodal metastasis (1.14). Based on these factors, we built and validated two nomograms predicting 1-year OS and 6-month PFS. CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLC patients can be estimated. These prognostic models provide a tool for research design and clinical decision making, such as patient stratification and therapy selection.
RCT Entities:
BACKGROUND: To determine prognostic factors and build a model to predict 1-year overall survival (OS) and 6-month progression-free survival (PFS) in advanced non-small-cell lung cancer (NSCLC) patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. MATERIALS AND METHODS: We analyzed 26 pretreatment clinical variables in 850 NSCLCpatients treated in the randomized Eastern Cooperative Oncology Group 4599 study. Univariate and multivariate analyses were performed to identify prognostic factors. Cox regression with 50% randomly sampled data was used to build nomograms with a prognostic score assigned to each factor. The model was validated with the remaining 50% of data. RESULTS: Eleven poor factors for OS (hazard ratio) were as follows: skin metastasis (4.49), body mass index less than 18.5 (2.09), increased serum lactate dehydrogenase (1.74), adrenal metastasis (1.52), performance status greater than 0 (1.45), low serum albumin (1.45), men (1.39), bone metastasis (1.39), large cell/not otherwise specified histology (1.29), mediastinal nodal metastasis (1.23), and treatment without bevacizumab (1.18). Seven poor factors for PFS were as follows: skin metastasis (3.13), treatment without bevacizumab (1.52), bone metastasis (1.41), liver metastasis (1.40), low serum albumin (1.39), performance status greater than 0 (1.21), and mediastinal nodal metastasis (1.14). Based on these factors, we built and validated two nomograms predicting 1-year OS and 6-month PFS. CONCLUSION: Using our proposed models, the probability of survival with first-line paclitaxel and carboplatin with or without bevacizumab in nonsquamous NSCLCpatients can be estimated. These prognostic models provide a tool for research design and clinical decision making, such as patient stratification and therapy selection.
Authors: Adrian M Jubb; Herbert I Hurwitz; Wei Bai; Eric B Holmgren; Patti Tobin; A Steven Guerrero; Fairooz Kabbinavar; Scott N Holden; William F Novotny; Gretchen D Frantz; Kenneth J Hillan; Hartmut Koeppen Journal: J Clin Oncol Date: 2005-12-19 Impact factor: 44.544
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: M Paesmans; J P Sculier; P Libert; G Bureau; G Dabouis; J Thiriaux; J Michel; O Van Cutsem; R Sergysels; P Mommen Journal: J Clin Oncol Date: 1995-05 Impact factor: 44.544
Authors: M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris Journal: Br J Cancer Date: 2003-09-01 Impact factor: 7.640
Authors: Jie Lin; Corey A Carter; Katherine A McGlynn; Shelia H Zahm; Joel A Nations; William F Anderson; Craig D Shriver; Kangmin Zhu Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome Journal: J Thorac Oncol Date: 2015-11 Impact factor: 15.609
Authors: Xiaofei Wang; Lin Gu; Ying Zhang; Daniel J Sargent; William Richards; Apar Kishor Ganti; Jeffery Crawford; Harvey Jay Cohen; Thomas Stinchcombe; Everett Vokes; Herbert Pang Journal: Lung Cancer Date: 2015-08-18 Impact factor: 5.705
Authors: Alex R Menter; Nikki M Carroll; Lori C Sakoda; Thomas Delate; Mark C Hornbrook; Rakesh K Jain; Lawrence H Kushi; Virginia P Quinn; Debra P Ritzwoller Journal: Clin Lung Cancer Date: 2016-08-20 Impact factor: 4.785
Authors: Daniel Shepshelovich; Wei Xu; Lin Lu; Aline Fares; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Xifeng Wu; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; M Catherine Brown; Geoffrey Liu; Rayjean J Hung Journal: J Thorac Oncol Date: 2019-06-01 Impact factor: 15.609